# Assura PLC (AGR.L): Navigating the Healthcare Real Estate Landscape with a Robust Dividend Yield

- Link: https://www.directorstalkinterviews.com/assura-plc-agr-l-navigating-the-healthcare-real-estate-landscape-with-a-robust-dividend-yield/4121202572
- Published: 2025-06-17T04:03:32+01:00
- Author: Madison Wilson

Assura PLC (AGR.L) stands out as a key player in the UK real estate investment trust(
REIT) sector, specialising in healthcare facilities. With a market capitalisation
of $1.63 billion, Assura plays an instrumental role in providing healthcare infrastructure,
boasting a portfolio of over 600 buildings that serve more than six million patients
across the UK. Based in Altrincham, it is a noteworthy constituent of the [FTSE 250](https://www.directorstalkinterviews.com/news/ftse-250)
and EPRA indices.

The current share price of Assura stands at 50.15 GBp, marking the upper boundary
of its 52-week range. Despite a modest price change of 0.05 (0.00%), the company’s
stability in the real estate sector offers a unique proposition for investors seeking
exposure to healthcare infrastructure.

One of the significant aspects of Assura’s financial performance is its substantial
dividend yield of 6.71%. While this figure is attractive, it’s important to note
the high payout ratio of 158.10%, which may suggest that the company is distributing
more to shareholders than it earns in net income. This situation might raise questions
about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends in the long term, yet it also highlights the REIT’s commitment
to returning value to investors.

Assura’s revenue growth of 8.50% is commendable, showcasing its ability to enhance
its financial performance amidst a challenging economic environment. However, the
absence of a trailing P/E ratio and a high forward P/E of 1,388.04 suggest investors
should approach valuation metrics cautiously. The company’s earnings per share (
EPS) is currently at 0.02, and the return on equity (ROE) stands at 4.23%, indicating
a moderate level of profitability relative to shareholder equity.

The technical indicators present a mixed outlook. The 50-day and 200-day moving 
averages are at 48.52 and 42.29, respectively, indicating a recent upward trend 
in share price. However, with an RSI (14) of 78.21, the stock appears to be in overbought
territory, which may suggest a potential price correction.

Analyst ratings show a balanced perspective with two buy and two hold ratings, and
no sell ratings, indicating confidence in the stock’s stability. The target price
range of 48.00 to 51.00 GBp suggests a potential downside of -0.96%, aligning closely
with the current market price.

Assura plc’s strategic focus on developing healthcare infrastructure aligns with
its ESG initiatives, encapsulated in its “The Bigger Picture” strategy, which underscores
its commitment to environmental sustainability, community support, and robust business
practices. With a portfolio valued at £2.7 billion as of March 2024, the company
continues to reinforce its leadership in the healthcare property investment sector.

For investors, Assura offers a compelling combination of stable income through dividends
and growth potential in a niche market segment. While the high dividend payout ratio
and valuation metrics warrant careful consideration, the company’s entrenched position
in the UK healthcare infrastructure domain provides a resilient foundation for long-
term investment.

Share on:
